Synapse - Shanu Modi

Results (268)

Safety of a novel capecitabine dosing schedule when combined with lapatinib in patients with HER2-positive metastatic breast cancer refractory to trastuzumab

Meeting Abstract

Traina, T. A.; Theodoulou, M.; Feigin, K.; Patil, S.; Geneus, S.; Modi, S.; Fornier, M.; Lake, D.; Norton, L.; Hudis, C.
Journal of Clinical Oncology (2009)

Fulltext@MSK | Save

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+breast cancer

Meeting Abstract

Krop, I. E.; Mita, M.; Burris, H. A.; Birkner, M.; Girish, S.; Tibbitts, J.; Holden, S. N.; Lutzker, S. G.; Modi, S.
Cancer Research (2009)

Fulltext@MSK | Save

Dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2/neu-positive breast cancer is not feasible due to excessive diarrhea: Updated results

Meeting Abstract

Dang, C.; Lin, N.; Moy, B.; Come, S.; Lake, D.; Theodoulou, M.; Troso-Sandoval, T.; Dickler, M.; Gorsky, M.; D'Andrea, G.; more...
Cancer Research (2009)

Fulltext@MSK | Save

Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)

Meeting Abstract

Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC)

Meeting Abstract

Holden, S. N.; Beeram, M.; Krop, I. E.; Burris, H. A.; Birkner, M.; Girish, S.; Tibbitts, J.; Lutzker, S. G.; Modi, S.
Journal of Clinical Oncology (2008)

Fulltext@MSK | Save

Preliminary safety results of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by weekly paclitaxel (P) with trastuzumab (T) and lapatinib (L) in HER2 overexpressed/amplified breast cancer (BCA)